Table 2.
Statistical analysis of 111In-PSMA-617 and 111In-RM2 bindings according to clinico-biological parameters (pathological size, Gleason score, prostate-specific antigen (PSA) value, and metastatic risk). Non-parametric one-way ANOVA (Kruskal-Wallis test) and non-parametric t test (Wilcoxon test). p < 0.05 was considered significant
| Biological parameters | n | 111In-PSMA-617 | 111In-RM2 | p value |
|---|---|---|---|---|
| Pathological size | ||||
| pT2 | 8 | 66.00 ± 3.65% | 9.17 ± 2.17% | 0.0078 |
| pT3&4 | 11 | 54.82 ± 4.45% | 2.82 ± 1.28% | 0.0010 |
| p value | 0.105 | 0.161 | ||
| Gleason score | ||||
| 6 | 5 | 64.60 ± 4.83% | 14.67 ± 3.96% | 0.0625 |
| 7 | 12 | 54.50 ± 4.87% | 2.58 ± 1.19% | 0.0005 |
| 8–9 | 3 | 62.33 ± 8.73% | 0.0 ± 0.0% | 0.0065 |
| p value | 0.5554 | 0.0019 | ||
| PSA value | ||||
| < 10 ng/mL | 5 | 64.60 ± 4.83% | 14.67 ± 3.96% | 0.0625 |
| ≥ 10 ng/mL | 15 | 56.07 ± 4.04% | 2.07 ± 0.98% | < 0.0001 |
| p value | 0.404 | 0.0012 | ||
| Metastatic risk | ||||
| Low | 5 | 64.60 ± 4.83% | 14.67 ± 3.96% | 0.0625 |
| Intermediate | 7 | 58.86 ± 4.90% | 2.86 ± 1.86% | 0.0156 |
| High | 8 | 53.63 ± 6.44% | 1.38 ± 0.94% | 0.0078 |
| p value | 0.665 | 0.0046 | ||
| Total | 20 | 58.2 ± 14.82% | 5.2 ± 7.65% | < 0.0001 |